May 4, 2018 8:30am-2:30pm
In partnership with EY and Scientific American, Bioethics International is hosting a Forum on what it means to be a purpose driven, patient-centered and ethical pharma and health-innovation company.
Location: New York, NY
March 12, 2019 — March 14, 2019
Bioethics International and eyeforpharma will collaboratively draft a global code of ethics.
April 16, 2019 — April 17, 2019
At this event you can expect 700+ attendees who will come together to:
Put patients first by understanding pharma’s new value paradigm and embed it in your business
Unleash the power of data with smart data sourcing and analysis techniques from the smartest tech
Become the trusted partner by building real solutions through long-term collaborations based on trust and transparency
The New York Times interviewed our founder, Jennifer Miller, on FDA Commissioner Dr. Scott Gottlieb's clinical trial transparency initiatives. She discussed his new pilot, launched last month, which selects 9 recently-approved drugs, whose sponsors (generally pharmaceutical companies) volunteer to participate, to post portions of Clinical Study Reports (CSRs) from their pivotal trials on FDA's website…
February 12, 2018
This week we focused on the ethics of Big Data, publishing an article titled, Big Data Probably Knows More About You Than Your Friends Do, in Leaps Mag. The article discusses the promises and perils of big data and concludes with a way to manage your data wealth. To read the full article click here.
February 7, 2018
Jeremy Puthumana, MS; Jennifer E. Miller, PhD; Jeanie Kim, JD; et al Joseph S. Ross, MD, MHS. JAMA Network Open. 2018;1(2):e180283. doi:10.1001/jamanetworkopen.2018.0283
The Right to Try Act of 2017 allows patients with life-threatening conditions to access investigational medicines outside clinical trials without oversight from the US Food and Drug Administration (FDA). A better understanding of existing expanded access programs can inform the consideration and implementation of both the federal Right to Try Act and state right-to-try laws.
Cross-sectional descriptive analysis of all clinical trials supporting 2014 Food and Drugs Administration (FDA)-approved new drug applications (NDAs) for novel drugs sponsored by large companies.